Efficacy and Safety of Reduced Dose Azacitidine in Elderly Patients with Myelodysplastic Syndromes
Objective
To analyze the efficacy and safety of low-dose azacitidine in treating elderly patients with myelodysplastic syndromes (MDS).
Methods
A total of 92 elderly MDS patients were divided into an observation group and a control group. The observation group received a low dose of azacitidine, while the control group received a standard dose. The clinical efficacy, overall survival, and adverse reactions of both groups were observed.
Results
After treatment, both groups showed significant improvement in hemoglobin and platelet levels. The total effective rate of the observation group was slightly lower than that of the control group. The incidence of adverse events in the control group was significantly higher than that in the observation group.
Conclusion
Reducing azacitidine dosage in the treatment of elderly MDS patients shows good efficacy and safety.
Practical Solutions and Value
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research into an easily accessible knowledge base for clinicians. Streamlining operations with mobile apps can support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance workflows and improve patient outcomes, reducing paper routines.
Learn more about how we can help at aidevmd.com.
